Economic realities and lack of funding prevent the use of artificial intelligence (AI) for breakthrough discoveries in the field of antibiotics. The market stands in the way of the revolution that AI could bring in the fight against antibiotic resistance. Nevertheless, there are significant investments, such as $60 million from the Gates Foundation, Novo Nordisk Foundation and Wellcome to support 18 projects in 17 countries aimed at discovering antibiotics against gram-negative bacteria. These projects use AI and machine learning to accelerate the discovery of new drugs. Imperial College London has been awarded £3.1 million for Klebsiella research, including open data and predictive models. Université de Montréal received $3.8 million to design Klebsiella-specific molecules using AI and microscopy. The results of these initiatives will be freely available to accelerate global research.